About
David founded CardioDx in 2004, and served as the President and Chief Executive Officer of the company until 2016. David drove the successful commercialization of the Corus CAD blood test with over 250,000 patients having received and benefited from the Corus CAD test. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer and Director of CareDx (formerly XDx, Inc.). Previously, he was the Founder, President, and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark). Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. Prior to OTN, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David continues to serve as a Director on both public and private Boards.
Position in the VCSift Database
- • 4 investors hold the Chief Strategy Officer (CSO) role in VCSift. David Levison is one of them.
- • 1,751 investors are based in California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- California, US
Contact Information
Find more investors like David
Search Investors